Lumen Bioscience today announced positive results from the RePreve Clinical Trial of oral LMN-201, an investigational ...
The financing round, led by investment firm Pekron, Investcorp-backed Sanos Group, Icelandic investment company Kaldbakur and Landvættir, an Icelandic ...
Rapport Therapeutics’ RAP-219 met its primary endpoint in acute bipolar mania with a 3.1-point placebo-adjusted improvement ...
A 36-participant pilot randomized trial will assess the feasibility of in-person UCLA PEERS in Italian routine care and ...
Penn State hockey has started 0-4 for the second time in program history and the first time since the shortened 2020-21 season with an embarrassing 5-2 loss to Robert Morris. The Colonials had not ...
Global greenhouse gas emissions remained at record levels in 2025 and the Earth will warm by 2.6°C by the end of the century, even if governments meet their latest climate commitments, according to a ...
CD206-targeted glucocorticoid 101-PGC-005 beat dexamethasone in 309-patient Phase 2/3 trial (HR 2.31); steroid-sparing data at ACR Poster 0122, Nov 8 ...
Hej and witam, explorers! We hope you’re all having a great time with The Baltic Powers. Today’s update is dedicated to ...
Resonance Consulting, founded by education researcher Dr. Johanna Groene, has begun implementing its Human-AI Stewardship ...
The strongest evidence for staying steady on your feet comes from a handful of moves most people can do by the kitchen counter.
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...
EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results